Amgen (NASDAQ:AMGN) Price Target Raised to $400.00

Key Points

• UBS raised its price target to $400 (from $390) and kept a "buy" rating—this and other upgrades contrast with a MarketBeat consensus "Hold" and an average analyst target of $356.24.
• Amgen beat quarterly estimates, reporting EPS of $5.29 (vs. $4.76 expected) and revenue of $9.87B (vs. $9.46B), and set FY2026 guidance of 21.600–23.000 EPS while the stock traded at $349.82 (down 0.3%).
• Institutional ownership is 76.50%, with major holders like Vanguard, State Street and Capital World Investors increasing their stakes in the latest quarter.

Amgen (NASDAQ:AMGN - Get Free Report) had its price target lifted by stock analysts at UBS Group from $390.00 to $400.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the medical research company's stock. UBS Group's price objective indicates a potential upside of 14.34% from the company's previous close.

AMGN has been the topic of several other reports. Mizuho increased their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a research report on Tuesday, February 10th. Argus upped their target price on shares of Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. TD Cowen reiterated a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Weiss Ratings reissued a "buy (b)" rating on shares of Amgen in a research report on Monday, December 29th. Finally, Royal Bank Of Canada boosted their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $356.24.

Amgen Stock Down 0.3%

Amgen stock traded down $1.20 on Monday, hitting $349.82. 2,544,880 shares of the stock traded hands, compared to its average volume of 2,789,263. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a market cap of $188.79 billion, a P/E ratio of 24.58, a price-to-earnings-growth ratio of 3.30 and a beta of 0.47. The business's fifty day simple moving average is $363.87 and its 200 day simple moving average is $335.48. Amgen has a 1 year low of $261.43 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts' expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm's quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts forecast that Amgen will post 20.62 earnings per share for the current year.

Institutional Trading of Amgen

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the period. State Street Corp grew its holdings in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company's stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Capital World Investors grew its holdings in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company's stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. Capital International Investors grew its holdings in shares of Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock worth $5,414,296,000 after acquiring an additional 282,219 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company's stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.